"At Genentech I have the privilege to pursue basic and translational science in a cutting edge environment together with exceptional people who shares my desire to improve and advance patient outcomes."
I joined Genentech in May 2022 as a Senior Fellow in the recently established Peptide Therapeutics Department. I have a long-standing interest in peptides as therapeutics commencing during my graduate studies when I first got introduced to disulfide-rich venom peptides modulating ion channels involved in pain pathways. Ever since then, I have focused my research on how we can harness natural bioactive peptide’s intrinsic ‘drug-like’ properties to develop novel therapeutics, probes and diagnostics for treatment and diagnosis for diseases with unmet needs.
I was attracted to Genentech because of the company’s commitment to improving patient outcomes through scientific excellence in translational and basic science combined with a commitment to high quality mentoring and training through a vibrant postdoc program. With all the exciting new targets arising from our advancements in the -omics fields combined with the giant leaps being made in AI and machine learning, I am excited to pursue peptides as an alternative modality in the ever-growing Genentech therapeutic portfolio.
Genentech has a large and exciting postdoctoral program providing high quality training and opportunities for postdocs to access the latest science, and state-of-the-art technology and methodology, learning from leaders in the field. I value being a postdoc mentor as I enjoy working on cutting edge basic science projects with enthusiastic and driven fellows as they set out to shape their scientific career, and I feel privileged to have this role within Genentech. Postdoctoral fellows in my laboratory have the opportunity to pursue independent projects in development and discovery of disulfide-constrained peptides to probe biological questions and identify novel targets.
Journal of the American Chemical Society 2020 142 (50), 21178-21188